Genomic Alterations in Lung and Thyroid Cancer: Expert Guidance in Incorporating Molecular Testing to Deliver Precision Therapy

Download All
Gain expert insights from a team of oncology pathologists on the rationale for and optimal approach to testing for NTRK and RET genomic alterations in the treatment of lung and thyroid cancer.
Juan C. Hernandez-Prera, MD
Jeremy P. Segal, MD, PhD

ASCP 2022 Pathology Symposium

Download these slides from a live symposium at ASCP 2022 featuring guidance from a pathologist on best practices for biomarker testing in advanced thyroid cancer along with the latest clinical evidence on targeted therapies available for the treatment of RET-altered and BRAF V600E–positive disease.

Juan C. Hernandez-Prera, MD Released: September 13, 2022

Download these slides from a live symposium at ASCP 2022 featuring guidance from a pathologist on best practices for detection of gene fusions in advanced non-small-cell lung cancer along with the latest clinical evidence on targeted therapies available for the treatment of RET and NTRK fusion–positive disease.

Jeremy P. Segal, MD, PhD Released: September 14, 2022

In this on-demand webcast from a live symposium at ASCP 2022, pathology experts provide guidance on best practices for detection of targetable gene alterations in advanced non-small-cell lung cancer and thyroid cancer, including discussion of the latest clinical evidence for targeting disease with a RET alteration or NTRK fusion.

Juan C. Hernandez-Prera, MD Jeremy P. Segal, MD, PhD Physicians: maximum of 0.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.5 Medical Knowledge MOC points ABPath MOC: maximum of 0.5 Lifelong Learning points Released: October 24, 2022 Expired: October 23, 2023
Provided by Clinical Care Options, LLC in partnership with the American Society for Clinical Pathology.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Blueprint Medicines and Genentech, a member of the Roche Group
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings